O119 : Stopping tenofovir disoproxil fumarate (TDF) treatment after long term virologic suppression in HBeAg-negative CHB: Week 48 interim results from an ongoing randomized, controlled trial (“finite CHB”)

Abstract

O119 STOPPING TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT AFTER LONG TERM VIROLOGIC SUPPRESSION IN HBeAg-NEGATIVE CHB: WEEK 48 INTERIM RESULTS FROM AN ONGOING RANDOMIZED, CONTROLLED TRIAL (“FINITE CHB”) T. Berg, K.-G. Simon, S. Mauss, E. Schott, R. Heyne, D. Klass, C. Eisenbach, T.M. Welzel, R. Zachoval, G. Felten, J. Schulze zur Wiesch, M. Cornberg, E.B. Martins, L. Gallo, T. Warger, J. Petersen. Innere Medizin, Sektion Hepatologie, Universitatsklinikum, Leipzig, Gastroenterologische Gemeinschaftspraxis, Leverkusen, Zentrum HIV and Hepatogastroenterologie, Dusseldorf, Charite, Leberzentrum Checkpoint, Berlin, Innere Medizin I, Universitatsklinikum, Ulm, Universitatsklinikum, Heidelberg, J.W.-Goethe Universitat, Frankfurt a. Main, Klinikum der LMU, Munchen, Gastroenterologische Gemeinschaftspraxis, Herne, University Hamburg Eppendorf, Hamburg, Medizinische Hochschule, Hannover, Germany; Gilead Sciences, Foster City, United States; IFI Institut, Hamburg, Germany E-mail: lothar.gallo@gilead.com